
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is a leading developer and seller of products and solutions in the clinical diagnostics and life sciences markets. With a diverse geographical presence and a leadership position in dPCR technology, the company is well-positioned for long-term growth. Despite recent market challenges, the company's sales growth is expected to recover in 2027, driven by the resolution of idiosyncratic headwinds and management's efforts to improve margin profiles. Additionally, the potential monetization of Bio-Rad's significant ownership stake in Sartorius, which is set to increase in mid-2028, presents a compelling asset value. However, risks to the company's outlook include potential delays in end-market recovery, loss of market share in ddPCR, and challenges in M&A integration.
Bears say
Bio-Rad Laboratories is facing several challenges, including limited sustainability integration and a track record of heavy restructuring. In addition, the company's reliance on the clinical diagnostics market, which accounts for 60% of its sales, exposes it to potential risks. Furthermore, Bio-Rad's stake in Sartorius, which accounts for 33% ownership, may not provide enough value to offset these challenges. These factors, along with potential risks such as end market recovery delays and share losses in ddPCR, lead to our negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares